Postinflammatory hyperpigmentation
Postinflammatory hyperpigmentation is a cutaneous condition inoratidzwa nekuwedzera pigment paganda zvichitevera kuzvimba kweganda. Postinflammatory hyperpigmentation inogona kukonzerwa nekugara kwenguva refu kwezuva, kuzvimba, kana kumwe kukuvadzwa kweganda, kusanganisira izvo zvine chekuita neacne. Vanhu vane ganda rakasvibira vanowanzoita hyperpigmentation nekunyanya kuratidzwa nezuva.
☆ Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
References
Postinflammatory hyperpigmentation (PIH) idambudziko reganda rinowanzoitika mushure mekuputika kweganda kana kukuvara. Inowanzogara kwenguva yakareba uye yakaipisisa muvanhu vane ganda rakasvibira (Fitzpatrick skin types III–VI) . Kunyange zvazvo inowanzova nani pachayo, izvi zvinogona kutora nguva, saka kurapwa kunowanzodiwa kwenguva yakareba. Kubatanidza marapirwo akasiyana anoshanda zvakanyanya.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation ndiyo yakajairika sequelae yekuzvimba kweganda. Zvinowanzobata vanhu vane ganda rakasviba zvakanyanya uye kazhinji. Zvidzidzo zvinoratidza kuti nyaya dzakaita se postinflammatory hyperpigmentation ndezvimwe zvezvikonzero nei vanhu vane ganda rakasviba vachitsvaga dermatological care. Kurumidza kurapwa kwakakosha pakugadzirisa postinflammatory hyperpigmentation uye kazhinji kunotanga nekugadzirisa mamiriro ekutanga ekuzvimba. Mutsara wekutanga wekurapa unowanzo sanganisira kushandisa topical agents izvo zvinorerutsa ganda pamwe nesunscreen kudzivirira. Aya maajenti, senge hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , anogona kudzikisa zvakanyanyisa pigmentation. Pamusoro pezvo, retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy anoshandiswawo seanobvisa pigmenting agents, nemishonga mitsva iri kubuda. Nepo marapirwo emumusoro achiwanzo shanda kune-pamusoro-level hyperpigmentation, maitiro (laser, chemical peel) angave akadikanwa kune nyaya dzakasindimara. Zvakakosha kushandisa kungwarira nemishonga iyi kudzivirira kushatirwa uye kuipa kwe postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
